Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Dr. Orla Cloak on Manufacturing Excellence: Minaris Vision for Advanced Therapies

Shots:  Minaris is advancing its dual-business strategy through specialized Advanced Therapies and Advanced Testing units, enabling sponsors to streamline development, manufacturing, biosafety testing, and commercialization within one integrated global organization.   Minaris is focused on solving key cell & gene therapy manufacturing challenges by reducing variability, accelerating tech transfer, improving “first time right” execution, and lowering…
3 days ago

Read more

MAGAZINE

PharmaShots Magazine-May-2026 Edition

Shots: PharmaShots’ May Edition explores how AI is transforming commercial strategies across the healthcare ecosystem by enabling predictive analytics, personalized engagement, dynamic launch planning, and real-time omnichannel optimization while balancing compliance and measurable ROI. The magazine highlights key industry movements shaping global biopharma, including AI-driven drug discovery collaborations, strategic M&A activity, advancements in cell and…
May 14, 2026

Read more

NEWS

UCB to Acquire Neurona Therapeutics for ~$1.15B, Expanding into Regenerative Epilepsy Therapies

Shots: UCB has entered into a definitive agreement to acquire Neurona Therapeutics for up to $1.15B, including $650M upfront and up to $500M in potential milestones expected to close by end of Q2’26 The acquisition adds NRTX-1001, an investigational neuronal cell therapy currently in P-I/II study for drug-resistant mesial temporal lobe epilepsy, strengthening UCB’s neuroscience…
April 20, 2026

Read more

NEWS

Orca Bio Presents New Clinical Data On Orca-Q and Orca-T/CAR-T Combination Therapy at ASH 2025

Shots: Orca Bio reported positive P-I study data for Orca-Q, showing rapid neutrophil recovery, low acute/chronic GvHD, reduced infections, and low non-relapse mortality, including in patients treated without any GvHD prophylaxis Patients receiving Orca-Q with tacrolimus (Arm A, n=18) vs. without immunosuppression (Arm C, n=26) showed comparable survival and GvHD outcomes, with faster neutrophil engraftment…
December 9, 2025

Read more

NEWS

March Biosciences’ MB-105 Receives the Regenerative Medicine Advanced Therapy Designation for R/R CD5+ T-Cell Lymphoma

Shots: The US FDA has granted RMAT designation to MB-105 for the treatment of r/r CD5-positive T-cell lymphoma Designation was based on the ongoing P-II trial, which showed clinical activity with a favorable safety profile; initial data to be presented at ASH’25, with additional updates expected in 2026 March Bio will pursue clinical & commercial…
November 12, 2025

Read more

NEWS

Lyell Immunopharma Acquires Global Rights to LYL273 from Innovative Cellular Therapeutics in ~$860M Deal

Shots: Lyell has acquired global rights to LYL273 (excl. mainland China, Hong Kong, Macau & Taiwan) for the treatment of metastatic colorectal cancer & other GCC-expressing cancers from ICT As per the deal, ICT will receive $40M upfront, 1.9M Lyell shares, ~$30M in clinical, ~$115M in late-stage regulatory, & ~$675M in sales milestones, plus ~1.85M additional…
November 11, 2025

Read more

NEWS

Avant Technologies and Austrianova Form Joint Venture Klothonova to Develop Klotho-Based Cell Therapies

Shots: Avant Technologies and Austrianova signed a joint venture and licensing agreement to form Klothonova, a 50/50 Nevada-based Joint Venture focused on developing cell-based therapies using encapsulated Klotho-producing cells Under the terms of the agreement, Klothonova will leverage Austrianova’s proprietary cell-encapsulation technology to develop and commercialize therapies for Alzheimer’s disease, heart disease, cancer, kidney disease,…
September 19, 2025

Read more

Load more